Molecular Profile Detail

Request Content

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name	KIT W557_K558del KIT A829P
Gene Variant Detail	KIT A829P (gain of function) KIT W557_K558del (gain of function)
Relevant Treatment Approaches

Filtering

Case insensitive filtering will display rows if any text in any cell matches the filter term
Use simple literal full or partial string matches
Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
Click on any column header arrows to sort by that column
Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Filter rows:

Showing 1 to 10 of 10 entries

Molecular Profile	Indication/Tumor Type	Response Type	Relevant Treatment Approaches	Therapy Name	Approval Status	Evidence Type	Efficacy Evidence	References
KIT W557_K558del KIT A829P	Advanced Solid Tumor	sensitive		AZD3229	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT W557_K558del and KIT A829P demonstrated sensitivity to AZD3229 in culture, resulting in reduced cell viability (PMID: 32350132).	32350132
KIT W557_K558del KIT A829P	Advanced Solid Tumor	sensitive		Ripretinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT W557_K558del and KIT A829P demonstrated sensitivity to Qinlock (ripretinib) in culture, resulting in reduced cell viability (PMID: 32350132).	32350132
KIT W557_K558del KIT A829P	Advanced Solid Tumor	conflicting		Regorafenib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT W557_K558del and KIT A829P were sensitive to treatment with Stivarga (regorafenib), but demonstrated a decreased response compared to cells expressing KIT W557_K558del alone in culture (PMID: 32350132).	32350132
KIT W557_K558del KIT A829P	Advanced Solid Tumor	sensitive		Avapritinib	Preclinical - Cell culture	Actionable	In a preclinical study, Ayvakit (avapritinib) treatment resulted in decreased viability of transformed cells expressing KIT W557_K558del and KIT A829P in culture, but was less effective compared to other treatments (PMID: 32350132).	32350132
KIT W557_K558del KIT A829P	Advanced Solid Tumor	resistant		Sunitinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT W557_K558del and KIT A829P demonstrated resistance to Sutent (sunitinib) in culture (PMID: 32350132).	32350132
KIT W557_K558del KIT A829P	Advanced Solid Tumor	resistant		Imatinib	Preclinical - Cell culture	Actionable	In a preclinical study, transformed cells expressing KIT W557_K558del and KIT A829P demonstrated resistance to Gleevec (imatinib) in culture (PMID: 32350132).	32350132
KIT W557_K558del KIT A829P	Advanced Solid Tumor	resistant		Sunitinib	Preclinical - Biochemical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT A829P were resistant to Sutent (sunitinib) in an in vitro kinase assay (PMID: 25239608).	25239608
KIT W557_K558del KIT A829P	Advanced Solid Tumor	sensitive		Ponatinib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT A829P were sensitive to Iclusig (ponatinib) in an in vitro kinase assay (PMID: 25239608).	25239608
KIT W557_K558del KIT A829P	Advanced Solid Tumor	resistant		Imatinib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT A829P were resistant to Gleevec (imatinib) in an in vitro kinase assay (PMID: 25239608).	25239608
KIT W557_K558del KIT A829P	Advanced Solid Tumor	conflicting		Regorafenib	Preclinical	Actionable	In a preclinical study, transformed cells co-expressing KIT W557_K558del and KIT A829P were resistant to Stivarga (regorafenib) in an in vitro kinase assay (PMID: 25239608).	25239608

Showing 1 to 10 of 10 entries

Filter rows: